Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression

Clin Cancer Res. 2004 May 15;10(10):3572-5.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow / pathology
  • Cell Line, Tumor
  • Chromosomes, Human, Pair 17*
  • Diphtheria Toxin / chemistry*
  • Diphtheria Toxin / therapeutic use
  • Female
  • Gene Deletion*
  • Humans
  • Interleukin-2 / chemistry*
  • Interleukin-2 / therapeutic use
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Male
  • Middle Aged
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Prognosis
  • Receptors, Interleukin-2 / biosynthesis
  • Recombinant Fusion Proteins / chemistry*
  • Recombinant Fusion Proteins / therapeutic use

Substances

  • Antineoplastic Agents
  • Diphtheria Toxin
  • Interleukin-2
  • Receptors, Interleukin-2
  • Recombinant Fusion Proteins
  • denileukin diftitox